

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 25, 2011

**Lightlake Therapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction of  
incorporation)

333-139915  
(Commission File Number)

N/A  
(IRS Employer  
Identification No.)

**54 Baker Street, 6<sup>th</sup> Floor**  
**London, England W1U 7BU**  
(Address of principal executive offices, including zip code)

44-207-034-1943  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

On August 24, 2011, the Registrant released a press release announcing the start date of the Phase II Clinical Trials of its Binge Eating Disorder Treatment. More information can be found in the press release included as an exhibit to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits. The following exhibit is being filed herewith this Current Report on Form 8-K

99.1 [Press Release of Lightlake Therapeutics, Inc. dated August 24, 2011.](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 25, 2011

By: /s/ Dr. Roger Crystal  
Dr. Roger Crystal

Chief Executive Officer

**Exhibit 99.1**

***For Immediate Release***

**Lightlake Therapeutics Inc. Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment**

LONDON, ENGLAND, August 24, 2011 – Lightlake Therapeutics Inc. (OTCBB: LLTP) (“Lightlake” or “the Company”), an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011

Dr. Roger Crystal, CEO of Lightlake commented, “We are excited to commence the definitive stage of testing of a product that we believe will be a solution to a disease thought to affect a significant proportion of obese and overweight patients today. We recently completed stability testing in an effort to ensure that our nasal spray adheres to internationally recognised safety standards in delivering an effective treatment. Moreover, we have an excellent control group in place, as we were able to select 138 patients from over 900 applicants wanting to participate in our trials in Helsinki. Dr. David Sinclair, our Chief Scientific Officer, revolutionized the way we treat alcoholism and drug addiction through his research into opioid antagonists, and we are confident that in working with him, we can develop an opioid antagonist derived nasal spray for the treatment of those with Binge Eating Disorder.”

In addition to treating patients with Binge Eating Disorder, Lightlake believes its nasal spray could also be beneficial for those with bingeing behaviour, which is thought to exist in one third of obese patients. The Company projects that its Phase II trials will be completed early next year and if successful, Lightlake plans to conduct its Phase III at Imperial College London and other international institutions. The Company will work with Celesio AG to develop a pharmacist delivered treatment program, and intends to establish similar commercial relationships over the next 12 months.

**About Lightlake Therapeutics Inc.**

Lightlake Therapeutics is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictive disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of binge eating. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.

---

## Safe Harbor

*This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.*

### Investor Contact:

Mr. Kevin Fickle, President  
NUWA Group LLC.  
Tel: +1-925-330-8315  
Email: [kevin@nuwagroup.com](mailto:kevin@nuwagroup.com)

### Company Contact:

Lightlake Therapeutics Inc.  
Dr. Roger Crystal, CEO  
Email: [roger.crystal@lightlaketherapeutics.com](mailto:roger.crystal@lightlaketherapeutics.com)  
or  
Lightlake Therapeutics Inc.  
Dr. Michael Sinclair, Chairman  
Email [michael.sinclair@lightlaketherapeutics.com](mailto:michael.sinclair@lightlaketherapeutics.com)